CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
We are very excited to launch our new website! Please take a few moments to click around and explore...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...